title: Cost-effectiveness of liquid-based cytology with or without hybrid-capture II HPV test compared with conventional Pap smears: a study by the French Society of Clinical Cytology.
abstract: Many articles concerning conventional Pap smears, ThinPrep liquid-based cytology (LBC) and Hybrid-Capture II HPV test (HC II) have been published. This study, carried out by the French Society of Clinical Cytology, may be conspicuous for several reasons: it was financially independent; it compared the efficiency of the conventional Pap smear and LBC, of the conventional Pap smear and HC II, and included an economic study based on real costs; for all the women, a "gold standard" reference method, colposcopy, was available and biopsies were performed whenever a lesion was detected; The conventional Pap smear, the LBC (split-sample technique), the colposcopy, and the biopsies were done at the same time. This study included 2,585 women shared into two groups: a group A of a high-risk population, a group B of a screening population. The statistical analysis of the results showed that conventional Pap smears consistently had superior or equivalent sensitivity and specificity than LBC for the lesions at threshold CIN-I (Cervical Intraepithelial Neoplasia) or CIN-II or higher. It underlined the low specificity of the HC II. Finally, the LBC mean cost was never covered by the Social Security tariff.
authors.affiliation: Service d'Anatomie et de Cytologie Pathologiques, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris 7, France.
authors.forename: Béatrix
authors.initials: B
authors.lastname: Cochand-Priollet
authors.forename: Isabelle
authors.initials: I
authors.lastname: Cartier
authors.forename: Patricia
authors.initials: P
authors.lastname: de Cremoux
authors.forename: Catherine
authors.initials: C
authors.lastname: Le Galès
authors.forename: Marianne
authors.initials: M
authors.lastname: Ziol
authors.forename: Vincent
authors.initials: V
authors.lastname: Molinié
authors.forename: Alain
authors.initials: A
authors.lastname: Petitjean
authors.forename: Anne
authors.initials: A
authors.lastname: Dosda
authors.forename: Estelle
authors.initials: E
authors.lastname: Merea
authors.forename: Annonciade
authors.initials: A
authors.lastname: Biaggi
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gouget
authors.forename: Sylviane
authors.initials: S
authors.lastname: Arkwright
authors.forename: Marie-Cécile
authors.initials: MC
authors.lastname: Vacher-Lavenu
authors.forename: Philippe
authors.initials: P
authors.lastname: Vielh
authors.forename: Joël
authors.initials: J
authors.lastname: Coste
mesh_terms: D000328:Adult; D001706:Biopsy / Q000191:economics / Q000379:methods; D003362:Cost-Benefit Analysis; D005260:Female; D005602:France; D006801:Humans; D008403:Mass Screening; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000821:virology; D014626:Vaginal Smears / Q000191:economics* / Q000379:methods; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis* / Q000821:virology